The dawn phenomenon and the Somogyi effect - Two phenomena of morning hyperglycaemia

Endokrynologia Polska

Volumn 62, Issue 3, 2011, Pages 276-283

  Rybicka, Malwina ^a   Krysiak, Robert ^a   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Dawn phenomenon; Morning hyperglycaemia; Somogyi effect

Indexed keywords

GLUCOSE; INSULIN;

BLOOD GLUCOSE MONITORING; DIABETES MELLITUS; DIABETIC PATIENT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; REVIEW;

BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 79960765639     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. International Diabetes Federation. Diabetes Atlas. http://atlas.idf-bxl. org/content/diabetes. Accessed Oct 10, 2010.
2. American Diabetes Association. Standards of Medical Care in Diabetes - 2009. Diabetes Care 2009; 32 (Suppl 1): 13-61.
3. Sanusi H. The role of incretin on diabetes mellitus. Acta Med Indones 2009; 41: 205-212.
4. th ed. Wydawnictwo Uniwersytetu Jagiellońskiego, Kraków 2000: 255-268. (in Polish).
5. Takahashi Y, Kipnis DM, Daughaday WH. Growth hormone secretion during sleep. J Clin Invest 1968; 47: 2079-2090.
6. Touitou Y, Auzéby A, Camus F, Djeridane Y. Daily profiles of salivary and urinary melatonin and steroids in healthy prepubertal boys. J Pediatr Endocrinol Metab 2009; 22: 1009-1015.
7. de Weerth C, Zijl RH, Buitelaar JK. Development of cortisol circadian rhythm in infancy. Early Hum Dev 2003; 73: 39-52. (Pubitemid 37025684)
8. Cacciari E, Coccagna G, Cicognani A et al. Growth hormone release during sleep in growth-retarded children with normal response to pharmacological tests. Arch Dis Child 1978; 53: 487-490. (Pubitemid 8350259)
9. Kwarecki K, Zużewicz K. Czynnik ludzki w bezpieczeństwie pracy. Najczȩstsze kłopoty zdrowotne pracownika zmianowego. Bezpieczeństwo Pracy Nauka i Praktyka 2001; 9: 30-31. http://www.ciop.pl/5887.html Accessed October 12 2010. (in Polish)
10. th ed. Wydawnictwo Lekarskie PZWL, Warszawa 2004: 759. (in Polish)
11. Bowen HF, and Moorhouse JA. Glucose turnover and disposal in maturity-onset diabetes. J Clin Invest 1973; 52: 3033-3045.
12. Sheehan JP. Fasting hyperglycemia: etiology, diagnosis, and treatment. Diabetes Technol Ther 2004; 6: 525-533. (Pubitemid 39121381)
13. Mozersky RP, Bahl VK, Patel H et al. Fasting hyperglycemia in type I diabetes mellitus. J Am Osteopath Assoc 1993; 93: 769-774.
14. Fowelin J, Attvall S, von Schenck H et al. Effect of prolonged hyperglycemia on growth hormone levels and insulin sensitivity in insulin-dependent diabetes mellitus. Metabolism 1993; 42: 387-394. (Pubitemid 23073360)
15. Cryer PE, Binder C, Bolli GB et al. Hypoglycemia in IDDM. Diabetes 1989; 38: 1193-1199.
16. Bolli GB, Perriello G, Fanelli CG, De Feo P. Nocturnal plasma glucose control in type I diabetes mellitus. Diabetes Care 1993; 16 (Suppl 3): 71-89. (Pubitemid 23348323)
17. Manzella D. Dawn phenomenon or Somogyi effect? What's the difference? http://diabetesaboutcom/b/2007/11/19/dawn-phenomenon-or-somogyi-effect-whats- the-difference.htm. Accessed July 3, 2010.
18. Beaufrère B, Beylot M, Metz C et al. Dawn phenomenon in type 1 (insulin-dependent) diabetic adolescents: influence of nocturnal growth hormone secretion. Diabetologia 1988; 31: 607-611.
19. Carroll MF, Hardy KJ, Burge MR, Schade DS. Frequency of the dawn phenomenon in type 2 diabetes: implications for diabetes therapy. Diabetes Technol Ther 2002; 4: 595-605. (Pubitemid 35283322)
20. Holt R. Growth hormone: a potential treatment option in diabetes? Diabetes Voice 2003; 48: 22-24.
21. Diabetes Health Center: Dawn phenomenon and the Somogyi effect - overview. http://diabetes.webmd.com/tc/dawn-phenome-non-and-the-somogyi-effect-. Accessed July 3, 2010.
22. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007; 30: 263-269. (Pubitemid 46198328)
23. Bolli GB, Gerich JE. The "dawn phenomenon" - a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med 1984; 310: 746-750.
24. Kapellen TM, Heidtmann B, Bachmann J et al. Indications for insulin pump therapy in different age groups - an analysis of 1,567 children and adolescents. Diabet Med 2007; 24: 836-842. (Pubitemid 47093059)
25. Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract 2005; 11: 55-64. (Pubitemid 43073091)
26. Schaepelynck-Bélicar P, Vague Ph, Simonin G, Lassmann-Vague V. Improved metabolic control in diabetic adolescents using the continuous glucose monitoring system (CGMS). Diabetes Metab 2003; 2: 608-612. (Pubitemid 38082163)
27. Garnero T. Somogyi effect vs. dawn phenomenon. http://www.dlife.com/ dLife/do/ShowContent/inspiration-expert-advice/expert-columns/garnero-0106.html. Accessed July 3, 2010.
28. Szypowska A, Pańkowska E, Lipka M. Guidelines concerning insulin dosage in children and adolescents with type 1 diabetes on continuous subcutaneous insulin infusion. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 2006; 12: 45-50. (in Polish, Abstract in English)
29. Jarosz-Chobot P. Zastosowanie cia̧głego podskórnego wlewu insuliny (CSII) za pomoca̧ osobistych pomp insulinowych w leczeniu dzieci i młodzieży chorych na cukrzycȩ typu 1. Wiad Lek 2004; 57: 263-266. (in Polish)
30. Calabrese G, Bueti A, Santeusanio F et al. Continuous subcutaneous insulin infusion treatment in insulin-dependent diabetic patients: a comparison with conventional optimized treatment in a long-term study. Diabetes Care 1982; 5: 457-465. (Pubitemid 12015082)
31. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25: 593-598.
32. Krajewski R, Kurzawa R (eds). Protokół z posiedzenia 19/2008 Rady Konsultacyjnej Agencji Oceny Technologii Medycznych; Dec 8, 2008; Warszawa, Poland. (in Polish).
33. Pesić M, Zivić S, Radenković S et al. Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy. Vojnosanit Pregl 2007; 64: 247-252. (in Serbian, Abstract in English).
34. Da̧browski M, Nowakowski A. Skuteczność, bezpieczeństwo i tolerancja glarginy - długodziałaja̧ cego analogu insuliny u dorosłych chorych na cukrzycȩ typu 1 w codziennej praktyce klinicznej. Diabetologia Praktyczna 2007 (in language); 8: 113-121. (in Polish).
35. Perriello G, De Feo R, Torlone E et al. The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregnlation and insulin sensitivity. Diabetologia 1991; 34: 21-28.
36. Walker H. Clinical Chemistry 1971; 17: 1138.
37. Somogyi M. Exacerbation of diabetes by excess insulin action. Am J Med 1959; 26: 169-191.
38. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH Insulin, and ultralente human insulin and continuous subcutaneous infusion of onsulin Lispro. Diabetes 2000; 49: 2142-2148.
39. Raskin P. The Somogyi phenomenon. Sacred cow or bull? Arch Intern Med 1984; 144: 781-787.
40. Jones TW, Porter P, Sherwin RS et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998; 338: 1657-1662. (Pubitemid 28267910)
41. Cryer PE. Hierarchy of physiological responses to hypoglycemia: relevance to clinical hypoglycemia in type I (insulin dependent) diabetes mellitus. Horm Metab Res 1997; 29: 92-96. (Pubitemid 27209909)
42. Matyka KA, Crowne EC, Havel PJ et al. Counterregulation during spontaneous nocturnal hypoglycemia in prepubertal children with type 1 diabetes. Diabetes Care 1999; 22: 1144-1150. (Pubitemid 29293968)
43. Perriello G, De Feo P, Torlone E et al. The effect of asymptomatic nocturnal hypoglycemia on glycemic control in diabetes mellitus. N Engl J Med 1988; 319: 1233-1239. (Pubitemid 18267062)
44. Bolli GB, Gottesman IS, Campbell PJ et al. Glucose counterregulation and waning of insulin in the Somogyi phenomenon (posthypoglycemic hyperglycemia). N Engl J Med 1984; 311: 1214-1219. (Pubitemid 14021925)
45. Winter RJ. Profiles of metabolic control in diabetic children - frequency of asymptomatic nocturnal hypoglycemia. Metabolism 1981; 30: 666-672. (Pubitemid 12195016)
46. Tordjman KM, Havlin CE, Levandoski LA et al. Failure of nocturnal hypoglycemia to cause fasting hyperglycemia in patients with insulin-dependent diabetes mellitus. N Engl J Med 1987; 317: 1552-1559. (Pubitemid 18014382)
47. Guillod L, Comte-Perret S, Monbaron D, Gaillard RC, Ruiz J. Nocturnal hypoglycemia in type 1 diabetic patients: what can we learn with continuous glucose monitoring? Diabetes Metab 2007; 33: 360-365. (Pubitemid 350026461)
48. Høi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B. The Somogyi phenomenon revisited using continuous glucose monitoring in daily life. Diabetologia 2005; 48: 2437-2438. (Pubitemid 41618937)
49. Monnier L, Colette C, Rabasa-Lhoret R et al. Morning Hyperglycemic Excursions. A constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 2002; 25: 737-741.
50. Gale EAM, Kurtz AB, Tattersall RB. In search of the Somogyi effect. J Lancet 1980; 316: 279-282.
51. Hirsch IB, Smith LJ, Havlin CE et al. Failure of nocturnal hypoglycemia to cause daytime hyperglycemia in patients with IDDM. Diabetes Care 1990; 13: 133-142. (Pubitemid 20056203)
52. Cohen M, Zimmet PZ. Home blood-glucose monitoring: a new approach to the management of diabetes mellitus. Med J Aust 1980; 2: 713-716. (Pubitemid 11108752)
53. Frohlich-Reiterer EE, Ong KK, Regan F et al. A randomized cross-over trial to identify the optimal use of insulin glargine in prepubertal children using a three-times daily insulin regimen. Diabet Med 2007; 24: 1406-1411. (Pubitemid 350179432)
54. Matyka K, Ford-Adams M, Dunger DB. Hypoglycemia and counterregulation during childhood. Horm Res 2002; 57: 85-90.
55. Tone A, Iseda I, Higuchi C et al. Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes. Exp Clin Endocrinol Diabetes 2010; 118: 320-324.
56. Hompesch M, Ocheltree SM, Wondmagegnehu ET et al. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin 2009; 25: 2679-2687.